Diagnosing and treating hereditary angioedema (HAE) can be challenging, but it is particularly difficult when patients live in rural areas of the U.S., a study based on a survey of allergy and immunology specialists reported. “Misdiagnosis of symptoms, access to a specialist, and affording medications remain…
The Canadian Agency for Drugs and Technologies in Health (CADTH) has recommended Orladeyo (berotralstat) be reimbursed by public drug plans when used for the routine prevention of hereditary angioedema (HAE) attacks in patients 12 years and older. “We are still in need of additional options to help people…
A 61-year-old woman in the U.S. was diagnosed with acquired angioedema and an underlying lymphoproliferative disorder after she sought treatment in an emergency department for sudden tongue swelling and difficulties in talking and swallowing, according to a case study. Lymphoproliferative disorders are characterized by the uncontrolled production of lymphocytes,…
The number of cases of hereditary angioedema with normal C1 inhibitor (HAE-nl-C1INH) within the U.S. was estimated to be between 1,230 and 1,331 from May 2019 and April 2020, according to a survey conducted among U.S. physicians. Patients waited a mean of six years to receive a diagnosis, which…
Despite long-term preventive treatment, a 38-year-old woman with hereditary angioedema (HAE) with normal C1-inhibitor levels had severe episodes of disease worsening, as described in a recent case report. The life-threatening sequelae and decreased quality of life illustrate the need for more research with this rare form of HAE, according…
Women with hereditary angioedema (HAE) who have been pregnant multiple times did not experience outcomes of significant disease worsening during pregnancy, a study in Turkey found. A majority did report a greater frequency of HAE attacks during pregnancy, but this was not statistically significant, according to researchers. In patients…
The efficacy and safety of Takhzyro (lanadelumab) in preventing hereditary angioedema attacks are similar across different racial and ethnic groups, according to an analysis of data from a Phase 3 trial and its open-label extension study. However, with few patients from minorities participating in clinical trials, conclusions are…
Get regular updates to your inbox.